Jacobson Pharma Corporation Limited provided earnings guidance for the six months ended 30 September 2022. Based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2022 and the information currently available to the Board, the Group expected to record an increase of around 70% in the consolidated profit attributable to equity shareholders of the Company for the six months ended 30 September 2022 as compared to that for the six months ended 30 September 2021.